Department of Neurology, University Medical Center Göttingen and German Center for Neurodegenerative Diseases, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Departament de Bioquímica i Biologia Molecular i Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Mol Neurobiol. 2018 Sep;55(9):7588-7605. doi: 10.1007/s12035-018-0926-y. Epub 2018 Feb 10.
The presence of protein deposits is a common pathological hallmark in patients suffering from neurodegenerative conditions and other proteinopathies. Deciphering the molecular basis of protein misfolding and aggregation is a crucial step towards the full comprehension of the factors that trigger the onset of these diseases and for the development of efficient therapeutical strategies. In this regard, in vitro aggregation assays for misfolded proteins offer an excellent tool to study pathological processes of protein deposition under controlled conditions, where confounders can be easily discriminated. These methods are generally cost-effective and have been proved useful in many fields, including drug discovery and clinical diagnostics. Here, we review the bases of in vitro aggregation and seeding assays, recapitulate their main applications and offer a critical evaluation of their limitations. Comprehending the molecular mechanisms behind these assays and combining them with in vivo or cell-based experiments will maximize their potential and allow the necessary improvement to overcome some of the current drawbacks.
蛋白质沉积物的存在是患有神经退行性疾病和其他蛋白质病患者的常见病理标志。阐明蛋白质错误折叠和聚集的分子基础是全面理解引发这些疾病的因素以及开发有效治疗策略的关键步骤。在这方面,体外聚集测定法为错误折叠蛋白提供了一个极好的工具,可在受控条件下研究蛋白质沉积的病理过程,其中混杂因素很容易被区分。这些方法通常具有成本效益,并且已在许多领域得到证实,包括药物发现和临床诊断。在这里,我们回顾了体外聚集和接种测定法的基础,概括了它们的主要应用,并对其局限性进行了批判性评估。理解这些测定法背后的分子机制,并将其与体内或基于细胞的实验相结合,将最大限度地发挥它们的潜力,并允许进行必要的改进以克服当前的一些缺点。